Abstract: A veterinary extruded soft chew has as active pharmaceutical ingredients (APIs), milbemycin oxime or one of its salts, and praziquantel or one of its salts. The APIs are uniformly dispersed in a matrix having one or more fillers, a polyethylene glycol (PEG), a non-animal based palatant, a disintegrant, a humectant, an oil, water, and preservatives. Neither the milbemycin oxime or one of its salts, nor the praziquantel or one of its salts is coated, granulated or physically separated from the other APIs within the matrix. More importantly, the soft chew does not comprise any palatant of animal origin.

Abstract: A soft-chewable product (1) for oral administration, having at least one pair of score markings (5, 6) configured to favor a division of the product into doses (1a, 1b), the force required to divide the product (1) into doses (1a, 1b) along the at least one pair of score markings (5, 6) being between 10 and 60 N and the loss of mass during the division of the product (1) into doses (1a, 1b) being less than 0.5%.

Abstract: Deslorelin, in a medicinal or a non-medicinal product, for its use in chemical castration of a non-human mammal within 1 month after administration, wherein upon administration, the Cmax of deslorelin, at around 1 to 2 hours after administration, exceeds 7000 pg/mL and a deslorelin concentration in the non-human mammal plasma is at least 10 pg/mL. Also, a sustained release drug delivery system for implementing this use. Further, a method for chemically castrating a non-human animal including the steps of (a) administering an effective amount of deslorelin so as to obtain a Cmax concentration between 4000 pg/mL and 40000 pg/ml of plasma of deslorelin or an equivalent amount of a pharmaceutically acceptable salt thereof within first 24 h after injection; and thereafter, (b) administering a maintenance dose so that mean concentration is above 10 pg/ml of plasma of deslorelin or an equivalent amount of a pharmaceutically acceptable salt thereof.

Abstract: Deslorelin for its use in attenuation or reduction of urine and/or feces odor of a non-human animal, preferably a mammal, preferentially in a companion animal. In particular, a process for attenuating or reducing urine and/or feces odor in a non-human animal including a step of administering to the non-human animal a quantity of deslorelin such that the deslorelin plasma concentration in the non-human animal is higher than 10 pg/mL. Also, a process for down regulating levels of molecules in urine and/or feces of a non-human animal, which includes administering to the non-human animal a quantity of deslorelin.

Abstract: The present invention relates to a crystalline modification of Modoflaner 6-fluoro-N-(3-(2-iodo-4-(perfluoropropan-2-yl)-6-(trifluoromethyl)phenylcarbamoyl)-2-fluorophenyl)nicotinamide of formula (I):

Abstract: The disclosure is directed to glucocorticoids for the treatment of epithelial microbial infections in fluid-containing organ having a natural exterior orifice in mammals; this new therapeutic use finds particular interest in the treatment of epithelial microbial infections of ear (such as otitis extema), udder (such as mastitis), and uterus (such as endometritis).

Abstract: Soft chew formulations have at least one nutraceutical ingredient and/or at least one pharmaceutical active substance; no more than 6 wt. % oil, fat or a mixture thereof based on the total weight of the soft chew; and starch. At least 50 wt. % by weight of total starch present in the soft chew is provided by pregelatinized rice flour, and the soft chew contains substantially no palatable agent of animal origin.

Abstract: The present invention relates to diffusers for dogs and cats, containing formulations capable of passively diffusing semiochemical compositions.

Abstract: The disclosure is directed to glucocorticoids for the treatment of epithelial microbial infections in fluid-containing organ having a natural exterior orifice in mammals; this new therapeutic use finds particular interest in the treatment of epithelial microbial infections of ear (such as otitis extema), udder (such as mastitis), and uterus (such as endometritis).

Abstract: The disclosure is directed to glucocorticoids for the treatment of epithelial microbial infections in fluid-containing organ having a natural exterior orifice in mammals; this new therapeutic use finds particular interest in the treatment of epithelial microbial infections of ear (such as otitis externa), udder (such as mastitis), and uterus (such as endometritis).

Abstract: A device for protecting against shocks for a glass bottle is presented, having a body, a bottom and a distal portion successively comprising from the body, a shoulder, a collar and a neck, said device comprising a first cup engaging with the bottom and a second cup engaging with the shoulder, each of the cups having a projecting portion for damping shocks, along a transversal plane, beyond a zone of a larger diameter of the bottle. The projecting portion of at least one from among the first and the second cups includes a plurality of damping pads spaced apart from one another.

Abstract: The invention relates in particular to a device (100) for collecting a sample of a liquid in a container, characterized in that it has: a housing (10) with a longitudinal axis (AL); a component (20, 20?, 20?) comprising: a body (26) provided with at least one channel (21) having a proximal end (21p) and a distal end (21d); a receptacle (24) fixed with respect to the body (26) and situated in the continuation of the proximal end (21p) of said at least one channel (21), said component (20) being mounted rotatably with respect to the housing (10) about the longitudinal axis of this housing (10) between a closure position, in which the distal end (21d) of said at least one channel (21) is closed by the housing (10), and an open position, in which the distal end (21d) of said at least one channel (21) is able to establish a fluidic communication with the container; and an elastic valve (30) housed in the receptacle (24).

Abstract: Low doses of fluralaner or another isoxazoline derivative are administered to an animal such as a pet, typically a dog or a cat, preferentially by administration of a repeated dose, at regular intervals or at varying intervals, each dose being of the same or different amount, which leads to efficacy against arthropods, especially fleas and ticks. Various regimens, galenic forms, posologies, therapeutic indications, combinations with other active or synergistic ingredients, and smart devices or methods for release of doses to the animal can be provided, alone or in combinations.

Abstract: A device for protecting against shocks for a glass bottle is presented, having a body, a bottom and a distal portion successively comprising from the body, a shoulder, a collar and a neck, said device comprising a first cup engaging with the bottom and a second cup engaging with the shoulder, each of the cups having a projecting portion for damping shocks, along a transversal plane, beyond a zone of a larger diameter of the bottle. The projecting portion of at least one from among the first and the second cups includes a plurality of damping pads spaced apart from one another.

Abstract: Multi-dose dispenser comprising: a product reservoir (14), on the X-axis, opening at a distal end through an outlet orifice and comprising a barrel (24); a piston (20) comprising a piston rod (38) having a rack and, at a distal end of the piston rod, a piston head (34) slidably mounted in the barrel (24) along the X-axis; a pawl mounted so as to be movable along the X-axis relative to the reservoir and configured to cooperate with the rack so as to drive the piston along the X-axis only in a forward direction of the piston in the barrel; a spring arranged to push the pawl back along the X-axis in a reverse direction; a case containing the pawl and at least a part of the piston; and a check valve arranged to seal the outlet orifice and allow only an outlet of product from the reservoir.

Abstract: The disclosure is directed to glucocorticoids for the treatment of epithelial microbial infections in fluid-containing organ having a natural exterior orifice in mammals; this new therapeutic use finds particular interest in the treatment of epithelial microbial infections of ear (such as otitis externa), udder (such as mastitis), and uterus (such as endometritis).

Abstract: Multi-dose dispenser comprising: a product reservoir (14), on the X-axis, opening at a distal end through an outlet orifice and comprising a barrel (24); a piston (20) comprising a piston rod (38) having a rack and, at a distal end of the piston rod, a piston head (34) slidably mounted in the barrel (24) along the X-axis; a pawl mounted so as to be movable along the X-axis relative to the reservoir and configured to cooperate with the rack so as to drive the piston along the X-axis only in a forward direction of the piston in the barrel; a spring arranged to push the pawl back along the X-axis in a reverse direction; a case containing the pawl and at least a part of the piston; and a check valve arranged to seal the outlet orifice and allow only an outlet of product from the reservoir.

Abstract: A compound of formula (I) in which R? represents a group —(CRaRb)n—X—(CRcRd)m—[Y—(CReRf)o]t—NR9R10 and X and Y independently represent a group —NR11-, a group —O— or a divalent 5-membered or 6-membered heterocyclic group comprising at least one nitrogen atom, and also the stereoisomers, mixtures of stereoisomers, and/or pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical or veterinary compositions containing the compound of formula (I) and also to the use thereof as medicament, more particularly in the treatment of bacterial, fungal, viral or parasitic infections. Also further disclosed are pharmaceutical or veterinary compositions including the compound of formula (I) in combination with an antibiotic other than such a compound of formula (I).

Abstract: The invention relates to compounds of formula (I), to the pharmaceutical compositions comprising same, and to the use thereof in the treatment of bacterial, fungal, viral and parasitic infections or in the treatment of cancer in humans or animals. In formula (I), R1 and R2 are as defined in claim 1.